Angela ScottFounder & Chief Operating Officer at TC Biopharm, UK at TC Biopharm, UK
Angela Scott has 40 years’ hands on experience in cancer research and commercial cell/gene therapy.
Originally with the Imperial Cancer Research Fund (Edinburgh), Angela became a key member of the ground-breaking team that cloned ‘Dolly the Sheep’. More recently Angela had a major role at AngelBio, establishing its reputation in the field of innovative cellular therapies. During her tenure, Angela contributed to clinical transition of several cell therapy products from the bench to bedside.
As founder, Chief Operating Officer and Board member of TC BioPharm, Angela has wide ranging responsibilities – directing new product development, GMP manufacture of clinical product (to treat cancer patients), QA/QC; clinical, regulatory, business development and finance functions.
Angela has advised the UK Government on stem cell policy and practice and is regarded as a KOL cell-based product translation.